• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Biohaven's ALS drug fails to meet study goals

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 29, 2022 at 10:12: AM
via Biohaven Pharmaceutical Holding Company Ltd said on Thursday its experimental drug to treat amyotrophic lateral sclerosis (ALS) failed a clinical study, the second therapy by the drugmaker to fail trials in recent months.

article source
 

<



Similar threads

cafead
Pfizer&#039;s Biohaven bet pays off again as migraine nasal spray wins approval
Replies
0
Views
318
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
How Pfizer CEO Bourla&#039;s evening call brought Biohaven back into the M&amp;A fold
Replies
0
Views
334
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Biohaven&#039;s drug for neurological disease fails late-stage study
Replies
0
Views
109
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Buckle up AbbVie, Amgen: Biohaven&#039;s oral CGRP drug is gaining traction in migraine,...
Replies
0
Views
265
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Biohaven&#039;s Verdiperstat Falls Flat in Multiple System Atrophy
Replies
0
Views
98
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote